Gabor Oroszlan

Company: VRG Therapeutics

Job title: Project Manager, Silico Lead

Bio:

As an In Silico Lead, I manage the development and operational oversight of VRG’s proprietary miniprotein platform, AI-MPRO. I oversee in silico processes and guide the transition of early-stage projects into the in vitro pipeline. I have deep expertise in molecular biochemistry, structural biology, and cross-functional project management.
I am passionate about collaborating with innovative, high-performing, and motivated teams on cross-functional pharmaceutical projects to tackle emerging scientific challenges, advancing the development of new therapies and drug discovery. I believe that real success is achieved only within stimulating communities driven by purpose, passion, vision, and clear goals.

Seminars:

Comparing Structure-Based & Sequence-Based De Novo Design to Improve Precision & Scalability 9:00 am

Contrast the strengths of structure-based design (precision, epitope targeting) with the speed and scalability of sequence-based approaches Examine case studies highlighting how each approach performs across antigen diversity and design complexity Identify hybrid strategies that combine both approaches to balance early exploration with therapeutic relevance NEW COMPANY!Read more

day: Conference Day Two

Panel Discussion: From Hype to Impact – Realizing the Value of AI in Biologics Design 4:15 pm

What are the current limitations and tangible successes in applying AI/ML to biologics discovery and developability? How are organizations measuring ROI from computational investments — speed, cost, accuracy, or all three? What infrastructure, culture, and talent are needed to effectively scale AI adoption across discovery and development pipelines?Read more

day: Conference Day One